Global Two-Piece Empty Hard Capsule Market Research Report Information by Raw Material (Gelatin Hydroxypropyl Methylcellulose, Starch and Pullulan), By size, By End Users And by Region

Description

List of Tables

Global Two-Piece Empty Hard Capsule Market Research Report Information by Raw Material (Gelatin Hydroxypropyl Methylcellulose (HPMC), Starch and Pullulan), By size (Size "00" capsules, Size "0" capsules, Size "1" capsules, Size "2" capsules, others), By End Users (Pharmaceutical Companies, Health & Nutrition, Others) And by Region (North America, Europe, Asia-Pacific, And Rest of The World) - Forecast Till 2032

Market Synopsis

The size of the two-piece empty hard capsule market was estimated at USD 1.13 billion in 2023 and is expected to increase at a compound yearly growth rate (CAGR) of 7.08% from USD 1.20 billion in 2024 to USD 2.23 billion by 2032.

The market for two-piece empty hard capsules is expanding rapidly, driven mostly by the rising incidence of non-communicable diseases (NCDs). The World Health Organization (WHO) estimates that noncommunicable diseases (NCDs) would kill 41 million people year in 2023, making up 74% of all deaths globally. The demand for empty hard capsules has increased as a result of the increased use of pharmaceutical and nutraceutical therapies due to the rising prevalence of disorders including obesity, diabetes, and cardiovascular diseases around the world. These capsules are effective drug delivery systems that make it easier to provide different formulations to treat the complicated issues related to non-communicable diseases. Pharmaceutical companies are using two-piece empty hard capsules to encapsulate a wide range of medicinal substances, taking advantage of their adaptability as healthcare systems worldwide attempt to control and cure these common chronic illnesses.

Because the capsules are easy to swallow and hide the taste of pharmaceuticals, they also have a benefit in terms of patient compliance, particularly in long-term treatment regimes. This fits well with the larger industry trend of drug development methodologies that are patient centric.

Insights on Market Segments

Based on raw material, the global Two-Piece Empty Hard capsule segmentation comprises pullulan, gelatin, hydroxypropyl methylcellulose (HPMC), and starch.

Size-based market segmentation for two-piece empty hard capsules comprises of capsules with a "00" size, "0" size, "1" size, "2" size, and other sizes.

The end-user segmentation of the two-piece empty hard capsule market includes pharmaceutical businesses, health and nutrition, and other categories.

RegionalPerspectives

With the biggest market share of 36.60% in 2022, the North American two-piece empty hard capsule market is expected to grow at a 5.70% CAGR to reach over USD 0.71 billion by 2032. Nonetheless, throughout the course of the projection period, Asia-Pacific is expected to develop at the highest CAGR of 8.89%.

The two-piece empty hard capsule market in North America has a good future ahead of it, with steady growth predicted. Further market expansion is anticipated because of investments in healthcare infrastructure and rising public awareness of modern medical treatments.

Due to rising healthcare costs, the prevalence of chronic diseases, and technological improvements, the Europe Two-Piece Empty Hard Capsule Market had the second-largest market share.

The market for two-piece empty hard capsules in the Asia-Pacific region is anticipated to develop at the quickest rate between 2024 and 2032 due to the region's high patient population, rise in chronic illnesses, and advantageous regulatory framework. The expansion of major companies in the Two-Piece Empty Hard Capsule Market into this area is also propelling the growth of the regional market.

Principal Players

Important Businesses CapsCanada (Canada), Roxlor (US), Goerlich Pharma GmbH (Europe), Lonza (Switzerland), Qualicaps (US), Suheung (South Korea), ACG (India), Hunan Er-Kang Pharmaceutical Co. Ltd (China), Shanxi Guangsheng Medicinal Capsule Co., Ltd (China), and Bright Pharma Caps (US) are some of the companies that sell two-piece empty hard capsules on the market.

Product Code: MRFR/Pharma/4823-CR

1 MARKET INTRODUCTION

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF NON-COMMUNICABLE DISEASES .
- 4.2.2 GROWING DEMAND FOR NUTRACEUTICALS
- 4.2.3 ADVANCEMENTS IN CAPSULE TECHNOLOGY
4.3 RESTRAINTS
- 4.3.1 ALTERNATIVE DRUG DELIVERY FORMS
4.4 OPPORTUNITY
- 4.4.1 GROWING PREFERENCES TOWARDS PLANT BASED CAPSUELS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D AND DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET
- 5.3.1 IMPACT ON RESEARCH AND DEVELOPMENT
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON PRICING
5.4 AVERAGE UNIT PRICE OF TWO PIECE EMPTY HARD GELATIN CAPSULE
5.5 HS CODE OF TWO PIECE EMPTY HARD GELATIN CAPSULE

6 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY RAW MATERIAL

6.1 OVERVIEW
6.2 GELATIN
6.3 HYDROXYPROPYL METHYLCELLULOSE (HPMC)
6.4 STARCH AND PULLULAN

7 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY SIZE

7.1 OVERVIEW
7.2 SIZE "00" CAPSULES
7.3 SIZE "0" CAPSULES
7.4 SIZE "1" CAPSULES
7.5 SIZE "2" CAPSULES
7.6 OTHERS

8 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY END USER

8.1 OVERVIEW
8.2 PHARMACEUTICAL COMPANIES
8.3 HEALTH & NUTRITION
8.4 OTHERS

9 GLOBAL TWO-PIECE EMPTY HARD CAPSULE MARKET, BY REGION

9.1 GLOBAL
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 AUSTRALIA
- 9.4.5 SOUTH KOREA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST & AFRICA
- 9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2022
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 EXPANSION
10.7 LIST OF KEY PLAYERS IN SEA REGION
- 10.7.1 INDONESIA
- 10.7.2 TAIWAN
- 10.7.3 VIETNAM
- 10.7.4 MALAYSIA

11 COMPANY PROFILES

11.1 CAPSCANADA
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 ROXLOR
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 KEY STRATEGIES
11.3 GOERLICH PHARMA GMBH
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 LONZA
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 QUALICAPS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 SUHEUNG
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
11.7 ACG
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 HUNAN ER-KANG PHARMACEUTICAL CO. LTD.
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
11.9 SHANXI GUANGSHENG MEDICINAL CAPSULE CO., LTD,
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 BRIGHT PHARMA CAPS INC.
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
11.11 SHANDONG HEALSEE CAPSULE LTD.
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 SWOT ANALYSIS
- 11.11.6 KEY STRATEGIES
11.12 GDL CAPSULE
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL OVERVIEW
- 11.12.3 PRODUCTS OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 SWOT ANALYSIS
- 11.12.6 KEY STRATEGIES
11.13 JIUJIANG ANGTAI CAPSULE CO., LTD.
- 11.13.1 COMPANY OVERVIEW
- 11.13.2 FINANCIAL OVERVIEW
- 11.13.3 PRODUCTS OFFERED
- 11.13.4 KEY DEVELOPMENTS
- 11.13.5 KEY STRATEGIES
11.14 SHANXI JC BIOLOGICAL TECHNOLOGY CO
- 11.14.1 COMPANY OVERVIEW
- 11.14.2 FINANCIAL OVERVIEW
- 11.14.3 PRODUCTS OFFERED
- 11.14.4 KEY DEVELOPMENTS
- 11.14.5 KEY STRATEGIES
11.15 HEALTHCAPS INDIA
- 11.15.1 COMPANY OVERVIEW
- 11.15.2 FINANCIAL OVERVIEW
- 11.15.3 PRODUCTS OFFERED
- 11.15.4 KEY DEVELOPMENTS
- 11.15.5 SWOT ANALYSIS
- 11.15.6 KEY STRATEGIES